| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total | 1,135 | 1,266 | ||
| Total operating expenses | 3,292 | 2,284 | ||
| Operating loss | -3,292 | -2,284 | ||
| Financial expenses | -30 | 216 | ||
| Loss before income tax | -3,262 | -2,500 | ||
| Income taxes | 0 | 3 | ||
| Net loss | -3,262 | -2,503 | ||
| Net loss per share attributable to ordinary shareholders, basic (in dollars per share) | 2.88 | 4.32 | ||
| Net loss per share attributable to ordinary shareholders, diluted (in dollars per share) | 2.88 | 4.32 | ||
| Weighted average number of ordinary shares outstanding used in computation of diluted loss per share | 1,132,658 | 579,523 | ||
| Weighted average number of shares outstanding, basic | 1,132,658 | 579,523 | ||
Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics Corp (SLXN)